Sigma Planning Corp increased its stake in Chemours Company (The) (NYSE:CC) by 13.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 78,997 shares of the specialty chemicals company’s stock after buying an additional 9,653 shares during the period. Sigma Planning Corp’s holdings in Chemours Company (The) were worth $2,996,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Financial Architects Inc increased its stake in shares of Chemours Company (The) by 1,230.3% in the second quarter. Financial Architects Inc now owns 2,940 shares of the specialty chemicals company’s stock valued at $111,000 after buying an additional 2,719 shares in the last quarter. Ropes Wealth Advisors LLC increased its stake in shares of Chemours Company (The) by 82.4% in the first quarter. Ropes Wealth Advisors LLC now owns 3,099 shares of the specialty chemicals company’s stock valued at $119,000 after buying an additional 1,400 shares in the last quarter. Benjamin F. Edwards & Company Inc. increased its stake in shares of Chemours Company (The) by 2,138.8% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 3,112 shares of the specialty chemicals company’s stock valued at $118,000 after buying an additional 2,973 shares in the last quarter. Schroder Investment Management Group bought a new stake in shares of Chemours Company (The) during the first quarter valued at $156,000. Finally, Cypress Capital Management LLC WY increased its stake in shares of Chemours Company (The) by 1.9% in the first quarter. Cypress Capital Management LLC WY now owns 4,196 shares of the specialty chemicals company’s stock valued at $162,000 after buying an additional 80 shares in the last quarter. 75.21% of the stock is currently owned by institutional investors.

Shares of Chemours Company (NYSE CC) opened at 46.34 on Friday. Chemours Company has a 1-year low of $11.33 and a 1-year high of $51.51. The stock has a market capitalization of $8.56 billion, a price-to-earnings ratio of 30.33 and a beta of 3.63. The stock’s 50 day moving average is $43.52 and its 200 day moving average is $38.05.

Chemours Company (The) (NYSE:CC) last issued its quarterly earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.02. Chemours Company (The) had a net margin of 4.96% and a return on equity of 122.97%. The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period in the previous year, the business posted $0.27 earnings per share. The business’s revenue was up 14.8% compared to the same quarter last year. On average, equities analysts forecast that Chemours Company will post $3.51 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Thursday, August 17th will be paid a dividend of $0.03 per share. The ex-dividend date of this dividend is Tuesday, August 15th. This represents a $0.12 dividend on an annualized basis and a dividend yield of 0.26%. Chemours Company (The)’s dividend payout ratio (DPR) is 8.11%.

COPYRIGHT VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://www.watchlistnews.com/sigma-planning-corp-has-3-million-stake-in-chemours-company-the-cc/1478362.html.

Several brokerages have weighed in on CC. UBS AG reaffirmed a “sell” rating and set a $36.00 price target (up from $35.00) on shares of Chemours Company (The) in a research report on Wednesday, June 14th. BidaskClub lowered shares of Chemours Company (The) from a “buy” rating to a “hold” rating in a research note on Friday. J P Morgan Chase & Co increased their target price on shares of Chemours Company (The) to $55.00 and gave the stock an “overweight” rating in a research note on Friday, August 4th. Argus reissued a “buy” rating and set a $55.00 target price (up from $50.00) on shares of Chemours Company (The) in a research note on Thursday. Finally, Jefferies Group LLC increased their target price on shares of Chemours Company (The) to $60.00 and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $51.50.

In other news, insider Paul Kirsch sold 19,036 shares of the business’s stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $41.42, for a total transaction of $788,471.12. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Erich Parker sold 4,908 shares of the business’s stock in a transaction dated Tuesday, May 16th. The stock was sold at an average price of $45.53, for a total transaction of $223,461.24. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

About Chemours Company (The)

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemours Company (The) (NYSE:CC).

Institutional Ownership by Quarter for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with Analyst Ratings Network's FREE daily email newsletter.